| Metric | Q3'25 | Q4'25 | Change |
|---|---|---|---|
| Adjusted EPS (ex-notables) | $2.34 Q3 (+21% YoY) | $2.58 Q4 (+24% YoY) | accelerating growth |
| Variable Investment Income | $483M Q3 | $497M Q4 | steady at elevated levels |
| Group Benefits Adjusted Earnings | $457M Q3 (+6% YoY) | $465M Q4 (+12% YoY) | strong acceleration |
| Group Life Mortality Ratio | 83.3% Q3 | 81.1% Q4 | 240bps improvement, unsustainably good |
| Nonmedical Health Loss Ratio | 72.5% Q3 | 72.2% Q4 | flat but guidance range raised |
| RIS Adjusted Earnings | $423M Q3 (+15% YoY) | $454M Q4 (+18% YoY) | steady growth acceleration |
| Asia Adjusted Earnings | $473M Q3 (+36% YoY) | $444M Q4 (flat YoY) | major deceleration |
| Asia Sales Growth (constant currency) | 34% Q3 | 18% Q4 | 1600bps deceleration |
| MIM Assets Under Management | ~$630B Q3 | $742B Q4 | 17% sequential jump |
| Free Cash Flow Ratio | 81% two-year average | 81% maintained | well above 65-75% target |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.